Clinical Trial

Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

Study acronym: CAPTOR-BC
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 18, 2023 (before its estimated October 2024 completion). Its status may not reflect the trial's current state.
Summary
This is a single-arm, open-label phase IV study of patients with advanced HR+/HER2- breast cancer who are treated first line with ribociclib and standard of care endocrine treatment according to SmPC.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-07-08; most recent amendment 2023-04-14.
Status change: Not Yet Recruiting → Recruiting 2023-01-25
Trial Details
NCT Number NCT05452213
Lead Sponsor Institut fuer Frauengesundheit
Collaborators: AGO Breast Study Group e.V., Novartis Pharmaceuticals
Conditions Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer
Enrollment 1,000 participants
Start Date 2022-10-12
Primary Completion 2024-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2023-04-18